Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors

BACKGROUND: As immune checkpoint inhibitors (CPI) are increasingly approved for cancer treatment, hospitalizations related to severe immune-related adverse events (irAE) will increase. Here, we identify patients hospitalized due to irAEs and describe survival outcomes across irAE, CPI, and cancer ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverstein, Jordyn, Wright, Francis, Wang, Michelle, Young, Arabella, Kim, Daniel, De Dios, Kimberly, Brondfield, Sam, Quandt, Zoe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Immuno-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546826/
https://www.ncbi.nlm.nih.gov/pubmed/37335906
http://dx.doi.org/10.1093/oncolo/oyad135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546826/
https://www.ncbi.nlm.nih.gov/pubmed/37335906
http://dx.doi.org/10.1093/oncolo/oyad135

Ejemplares similares